Treatment of adults (≥18 yr) w/ mild, moderate, & severe infections caused by susceptible strains: Acute bacterial sinusitis due to
Strep pneumoniae,
H. influenzae, or
Moraxella catarrhalis; acute bacterial exacerbation of chronic bronchitis due to
Staph aureus,
Strep pneumoniae,
H. influenzae,
H. parainfluenzae, or
Moraxella catarrhalis; nosocomial pneumonia due to methicillin-susceptible
Staph aureus,
Pseudomonas aeruginosa,
Serratia marcescens,
E. coli,
Klebsiella pneumoniae,
H. influenzae, or
Strep pneumoniae; community-acquired pneumonia due to
Staph aureus,
Strep pneumoniae (including multidrug resistant strains),
H. influenzae,
H. parainfluenzae,
Klebsiella pneumoniae,
Moraxella catarrhalis,
Chlamydia pneumoniae,
Legionella pneumophila, or
Mycoplasma pneumoniae; complicated skin & soft tissue infections due to methicillin-susceptible
Staph aureus,
Enterococcus faecalis,
Strep pyogenes,
Proteus mirabilis; uncomplicated skin & soft tissue infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma wound infections, due to
Staph aureus or
Strep pyogenes; chronic bacterial prostatitis due to
E. coli,
Enterococcus faecalis, or
Staph epidermidis; complicated UTI (mild to moderate) due to
Enterococcus faecalis,
Enterobacter cloacae,
E. coli,
Klebsiella pneumoniae,
Proteus mirabilis, or
Pseudomonas aeruginosa; acute pyelonephritis (mild to moderate) caused by
E. coli; uncomplicated UTI (mild to moderate) due to
E. coli,
Klebsiella pneumoniae, or
Staph saprophyticus. Prevention of development of inhalational anthrax following exposure to
Bacillus anthracis.
Sign Out
